{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifboyl5ponkfwqcixek6g2gt2k27opfdneajmfevtyot2pj7dm3dy",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mf4lnf3qdkp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie4iiooseejzb7uptu5ewdvgun6geros4ocvkd3etoyoxlyixxdia"
    },
    "mimeType": "image/jpeg",
    "size": 76406
  },
  "path": "/2026/02/17/biotech-news-compass-psilocybin-data-for-fda/?utm_campaign=rss",
  "publishedAt": "2026-02-17T14:57:05.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "And other biotech news brought to you by The Readout newsletter",
  "title": "STAT+: Psilocybin data could be good enough for approval",
  "updatedAt": "2026-02-17T14:57:09.000Z"
}